Holen Sie sich die Stockscreener-App
25.24
0.83%
-0.21
Vorhandelsmarkt:
24.90
-0.34
-1.35%
Schlusskurs vom Vortag:
$25.45
Offen:
$25.45
24-Stunden-Volumen:
18.31M
Relative Volume:
1.84
Marktkapitalisierung:
$9.82B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-2.8912
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
+7.36%
1M Leistung:
-9.57%
6M Leistung:
-24.25%
1J Leistung:
-62.89%
1-Tages-Spanne:
$24.60
$25.49
1-Wochen-Bereich:
$23.35
$26.01
52-Wochen-Spanne:
$23.15
$67.96
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.24 | 9.90B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Inc. $MRNA Shares Sold by Voya Investment Management LLC - MarketBeat
Moderna, Inc.(NasdaqGS: MRNA) dropped from FTSE All-World Index - MarketScreener
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - The Augusta Chronicle
ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest - insights.citeline.com
Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 6.6%Should You Buy? - MarketBeat
Strs Ohio Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Swedbank AB Lowers Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Douglas Lane & Associates LLC Has $25.66 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Decide on COVID-19 shot at your own peril: ACIP - BioWorld MedTech
Moderna Wants Fed. Circ. Reversal Of Vax Patent Invalidation - Law360
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Waco Tribune-Herald
CDC vaccines panel votes unanimously to change COVID-19 vaccine recommendation (MRNA:NASDAQ) - Seeking Alpha
Is Moderna A Buy Or A Sell As CDC Weighs Its Covid Shot? - Investor's Business Daily
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
A Future Made in Canada: Moderna Launches the First Domestic mRNA Vaccines - Macleans.ca
Moderna (MRNA) Settles Patent Dispute with Alnylam - GuruFocus
Moderna, Alnylam settle patent row over COVID vaccine delivery technology - Seeking Alpha
Moderna to roll out first made-in-Canada COVID-19 vaccines this fall - The Globe and Mail
Valuation Update: Can Moderna Inc. deliver alphaJuly 2025 Short Interest & AI Driven Price Predictions - khodrobank.com
United States COVID-19 Vaccine Market Set for Transformative - openPR.com
Woodline Partners LP Has $6.93 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $101.98 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Hold" from Analysts - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Acadian Asset Management LLC - MarketBeat
Moderna settles Alnylam patent lawsuits over COVID vaccine technology | Business Information & News | FE - Westlaw Today
Moderna, Alnylam Agree to End Vaccine-Delivery Patent Lawsuits - Bloomberg Law News
Trend Review: Can Moderna Inc weather a recession2025 Volume Leaders & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna settles Alnylam patent lawsuits over COVID vaccine technology - Reuters
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):